BACKGROUND: At present, there is no pharmacological therapy that can cure Alzheimer’s disease. Treatment is only limited to preventing progression and controlling risk factors that worsen Alzheimer’s. Medium-chain triglycerides (MCT) are nutritional therapies that are being studied to prevent the progression of Alzheimer’s disease.
AIM: This study aims to see the effect of giving MCT to the value of percentage alternation Y-maze test and serum Aβ-42 levels as a marker of Alzheimer’s disease.
MATERIALS AND METHODS: This study is an experimental study using postp-test control group design. Samples from this study were 30 Sprague Dawley rats which were divided into positive control groups, negative controls, and three treatment groups. Positive control group and treatment were induced by Alzheimer’s by ovariectomy and d-galactose. After induction, MCT were given to the treatment group for 6 weeks. After treatment, the levels of Aβ-42 serum were examined by ELISA and cognitive function was examined by Y-maze. After that, the data were analyzed by ANOVA. p < 0.05 was said to be statistically significant.
RESULTS: The results showed that this study was found a moderate relationship with a positive pattern. This means that the higher the percentage alternation value, the higher the level of Aβ-42 in serum which indicates that the higher the percentage alternation value, the higher the clearance of Aβ-42.
CONCLUSION: This study concluded that the group of rats given MCT has a serum Aβ-42 level higher than the group of rats that were not given MCT.
Relationship between Amyloid-beta 42 Levels and Y-maze Alternation Values in Sprague Dawley Alzheimer’s Induction Received Medium-Chain Triglycerides Therapy
